Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. - Wikidata - awgldk - TriplyDB

Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial.

Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial.

http://www.wikidata.org/entity/Q34782162

about

Current and future treatment options in SIADH Usefulness of portal vein pressure for predicting the effects of tolvaptan in cirrhotic patients Do vasopressin V2 receptor antagonists benefit cirrhotics with refractory ascites?The conservative and interventional treatment of the complications of liver cirrhosis: Part 2 of a series on liver cirrhosis Hyponatremia in cirrhosis: pathophysiology and management Global analysis of the effects of the V2 receptor antagonist satavaptan on protein phosphorylation in collecting duct Management of hyponatremia.Cirrhosis and its complications: evidence based treatment.Therapeutic Potential of Spirooxindoles as Antiviral Agents Oral tolvaptan is safe and effective in chronic hyponatremia Hyponatremia: A practical approach.Clinical practice guideline on diagnosis and treatment of hyponatraemia.Short-term efficacy and safety of vasopressin receptor antagonists for treatment of hyponatremia.The treatment of vasopressin V2-receptor antagonists in cirrhosis patients with ascites: a meta-analysis of randomized controlled trials.Serum sodium, renal function, and survival of patients with end-stage liver disease.Improving survival in decompensated cirrhosis Hyponatremia in the intensive care unit: How to avoid a Zugzwang situation?Hyponatremia in cirrhosis and end-stage liver disease: treatment with the vasopressin V₂-receptor antagonist tolvaptan.Clinical management of SIADH.Vaptans and hyponatremia in critical patients Evaluation and management of patients with refractory ascites.Plasma copeptin and the risk of diabetes mellitus.Predictors of the Effect of Tolvaptan on the Prognosis of Cirrhosis.Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program.Predicting short-term survival after liver transplantation on eight score systems: a national report from China Liver Transplant Registry.Vasopressin-receptor antagonists.Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).The kidney in cirrhosis with portal hypertension.Vaptans for the treatment of hyponatremia.Arginine vasopressin (AVP) and treatment with arginine vasopressin receptor antagonists (vaptans) in congestive heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion (SIADH).The management of hospitalized patients with cirrhosis: the Mount Sinai experience and a guide for hospitalists.Vasopressin V2-receptor antagonists in patients with cirrhosis, ascites and hyponatremia.Meta-analysis: the safety and efficacy of vaptans (tolvaptan, satavaptan and lixivaptan) in cirrhosis with ascites or hyponatraemia.Hyponatraemia: more than just a marker of disease severity?Satavaptan treatment for ascites in patients with cirrhosis: a meta-analysis of effect on hepatic encephalopathy development.Hyponatremia: an update on current pharmacotherapy.Tolvaptan for the treatment of liver cirrhosis oedema.Low-dose tolvaptan for the treatment of dilutional hyponatremia in cirrhosis: a case report and literature review.Role of vaptans in the management of hydroelectrolytic imbalance in liver cirrhosis.Hyponatremia: A Review.

P2860

Q24652519-D3D2B633-9510-4619-9CA9-388DDECFB752 Q24658600-D0E85447-79CC-4707-88F9-6792CD2741C2 Q26778032-2A21B24C-B16C-4480-831A-ED255733C364 Q27009164-FECE1CED-9B6C-448E-8180-8AB1BBAB96B3 Q27027861-6C0DEF0A-8DEC-4197-951B-A71BD0240D48 Q28659266-673B8641-6652-481E-AEE9-A472E4B63DF7 Q33590642-B24CF876-5EC6-4980-99BB-87B1698FA2A0 Q33594931-207D30F2-E553-47E6-97A5-5B66FB984C17 Q33637160-D40F6026-4F7E-43BF-BB0B-229FD7D48DD0 Q33748535-466DE149-0502-4174-99E5-83D6ECFFD6F3 Q34319649-498A5BDB-E48D-4C70-A1E2-41A3C10C7297 Q34406779-86DE7722-0B0B-4AD4-B206-9A19BDE11A4C Q35275760-50C49A69-A8A4-4DC0-BFEB-7A83DC00FDB7 Q35657152-D194402D-FE94-418F-810A-9C18F59D207A Q35988332-B6ED1E60-6FF9-4B7A-A292-8BF172741890 Q36090423-2E75D50E-44F4-4868-8CA6-D7392BB0CC86 Q36265206-E0C9AE12-76AB-4688-A97E-3E8960A74D7D Q36319648-8FC747D8-22A5-40E4-A5EE-A7510F2BBFF9 Q36328081-143CEEBB-C829-4164-8D77-307424F85A00 Q37058365-059AC542-2796-4791-AA52-B7FA0B339703 Q37122130-8BA6E2FD-B14E-42D9-8CB1-AC4F3A684F6C Q37147707-D92CCF0E-0E62-4EE1-B47A-372F663C26CA Q37414345-9DE0D614-9057-4706-B268-F64FA6C4F97F Q37489472-3866EF4A-AB6B-48EC-8104-BDB176FF91F0 Q37638019-3DB5B56E-3E6F-4E64-B031-1AC3F4A9C69D Q37770574-6810724B-D305-4B24-A07A-186DE7A755DA Q37799214-4B2EDE9B-1260-4A4E-83CD-DF9FADF2A021 Q37802342-7C77C98D-2FB1-4E47-8B0B-16CEF1984FCD Q37833895-AF1FE947-B2F0-41C4-9416-7BF73146B111 Q37843827-11E5BD83-31CB-43CE-B60B-9FECE4E2F635 Q37854505-649EB67F-ED99-43A5-9597-1AB1B30388E3 Q38008650-8A526918-6CC7-4972-B76F-0ED1D3FCC201 Q38036326-5DDFECC2-727E-489F-8E1A-CDC33FDD3EDB Q38061001-63E69F6E-620A-4A83-8FE9-13332176C246 Q38086800-C0F14DFE-C8AE-440D-9E17-CA0103DE2AA9 Q38089919-445E00F6-FE88-4ADE-A480-095E1AD8E359 Q38200108-172E5FAE-A6D6-42D7-AFA8-6CCBB9EDFD75 Q38266482-446CE81D-A3F7-4FD7-B77B-4769BD100205 Q38271966-B9F9B94A-4775-4B44-A69A-4376E3BE9396 Q38319828-6C3E6E75-6DDD-49E7-8C99-0EB0F9B22012

P2860

Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial.

http://www.wikidata.org/entity/Q34782162

description

2008 nî lūn-bûn

@nan

2008 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Effects of satavaptan, a selec ...... onatremia: a randomized trial.

@ast

Effects of satavaptan, a selec ...... onatremia: a randomized trial.

@en

Effects of satavaptan, a selec ...... onatremia: a randomized trial.

@nl

type

label

Effects of satavaptan, a selec ...... onatremia: a randomized trial.

@ast

Effects of satavaptan, a selec ...... onatremia: a randomized trial.

@en

Effects of satavaptan, a selec ...... onatremia: a randomized trial.

@nl

prefLabel

Effects of satavaptan, a selec ...... onatremia: a randomized trial.

@ast

Effects of satavaptan, a selec ...... onatremia: a randomized trial.

@en

Effects of satavaptan, a selec ...... onatremia: a randomized trial.

@nl

P1433

Q34782162-09BF7C57-6EA5-43BD-A15B-8C78A3FE215A

P1476

Q34782162-46785B90-B14B-4CE4-B943-58F172500F8B

P2093

Q34782162-04E4C6D6-172C-45EC-AA41-242CFB98EF85

Q34782162-5018C4EF-A91C-4B67-B623-3BC5405AB52C

Q34782162-59671CB6-E023-4A33-A11D-96E4412C29A3

Q34782162-5B705DCE-80B6-46BF-ADE8-1D7D9AA67ED7

Q34782162-8F5FE6AF-085E-48AB-9943-6058DA31E056

Q34782162-F4FDAECB-B427-4740-BDBF-DCEA8FDE0DB3

Q34782162-FC5A5218-8EB4-48DE-9B75-4B0DFC7F3508

P2860

Q34782162-454DAFCE-F65F-46C1-9A42-B4A0E2D125C7

Q34782162-CEE49C8A-1007-4D9A-B4B2-ACF9137E9F71

P304

Q34782162-47102E1C-D327-4541-A388-D81E614EC8A9

P31

Q34782162-0A7FA0BC-B961-45A6-95BD-83EA17432123

P356

Q34782162-5B15DE48-116D-4B15-9928-423569103D07

P407

Q34782162-0FAEA685-62D3-4057-8129-577146FD12E9

P433

Q34782162-C8929145-4B97-401C-9DF0-D2BFDB356ABB

P478

Q34782162-0FEFD667-B6D7-4806-B04F-59992BFED8C1

P577

Q34782162-96086D3C-2F10-4D49-A920-A7B84CE123A1

P5875

Q34782162-08B12582-7895-489F-A737-21614967CD22

P698

Q34782162-49101AD4-A8A3-40AE-A3E6-8EC2CA38B8B5

P921

Q34782162-1dc9d4b8-9649-4e71-9782-a66ac5c38d4f

P356

P1433

P1476

Effects of satavaptan, a selec ...... onatremia: a randomized trial.

@en

P2093

Dan Olteanu

http://www.w3.org/2001/XMLSchema#string

Florence Wong

http://www.w3.org/2001/XMLSchema#string

Hugh Watson

http://www.w3.org/2001/XMLSchema#string

HypoCAT Study Investigators

http://www.w3.org/2001/XMLSchema#string

Luis Ruiz del Arbol

http://www.w3.org/2001/XMLSchema#string

Pere Ginès

http://www.w3.org/2001/XMLSchema#string

Slobodan Milutinovic

http://www.w3.org/2001/XMLSchema#string

P2860

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

Osmotic demyelination syndrome following correction of hyponatremia.

P304

204-213

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HEP.22293

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

48

http://www.w3.org/2001/XMLSchema#string

P577

2008-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5343215

http://www.w3.org/2001/XMLSchema#string

P698

18508290

http://www.w3.org/2001/XMLSchema#string

P921